Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia

The ability to detect residual levels of leukemic blasts (measurable residual disease, MRD) has already been integrated in the daily routine for treatment of patients with chronic myeloid and acute lymphoblastic leukemia. In acute myeloid leukemia (AML), a variety of mostly retrospective studies hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Jentzsch, Madlen, Schwind, Sebastian, Bach, Enrica, Stasik, Sebastian, Thiede, Christian, Platzbecker, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893483/
https://www.ncbi.nlm.nih.gov/pubmed/31652787
http://dx.doi.org/10.3390/cancers11111625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893483/
https://www.ncbi.nlm.nih.gov/pubmed/31652787
http://dx.doi.org/10.3390/cancers11111625

Ejemplares similares